SCHEMBL5564284

SCHEMBL5564284

O=C(O)c1cc2cccc(OCCN3CCOCC3)c2o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.59
POLB P06746 2/20 0.55
KDM4E B2RXH2 4/20 0.54
DRD1 P21728 1/20 0.51
DRD4 P21917 1/20 0.51
DRD5 P21918 1/20 0.51
CNR1 P21554 1/20 0.51
CNR2 P34972 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
USP2 O75604 1/20 0.47
MAOB P27338 1/20 0.47
PRKDC P78527 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5559235 0.91 HRH3 (0.52) RXFP1POLBKDM4EDRD1DRD4
SCHEMBL5558555 0.90 KDM4E (0.51) RXFP1POLBKDM4EDRD1DRD4
SCHEMBL7086519 0.86 RXFP1 (0.56) RXFP1POLBKDM4ECNR1CNR2
SCHEMBL5558971 0.79 LMNA (0.50) CNR2MEN1KMT2AALDH1A1MAPT
SCHEMBL5559654 0.78 RXFP1 (0.54) RXFP1POLBKDM4ECNR1CNR2
SCHEMBL5565438 0.77 LMNA (0.55) RXFP1KDM4ECNR2MEN1KMT2A
SCHEMBL21681926 0.76 POLB (0.62) POLBKDM4EDRD1DRD4DRD5
SCHEMBL6984399 0.76 KDM4E (0.56) RXFP1KDM4EMEN1KMT2AALDH1A1
SCHEMBL3056169 0.76 KDM4E (0.54) KDM4ETP53TSHRALDH1A1
SCHEMBL6408412 0.76 CYP1A2 (0.65) KDM4ETP53TSHRALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP claimed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP claimed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO claimed
US-7208491-B2 N-monoacylated o-phenylenediamines HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20040157841-A1 inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy HOFFMANN-LA ROCHE INC. 2004-08-12 US disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157841-A1 inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy HDAC1, HDAC11, HDAC7 RXFP1 2974/4885POLB 844/4885KDM4E 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.